My Community - Clinical Information


Sanofi Genzyme Gaucher Research

1. A Study of the Efficacy and Safety of Genz-112638 in
Type 1 Gaucher Patients
This study was designed to determine the efficacy, safety and pharmacokinetics of Genz-112638 in men and women with Type 1 Gaucher disease. Each patient's duration of participation is expected to be approximately 26 months. The primary outcomes measured will be changes in hemoglobin and platelet levels and spleen volume compared to baseline.

For more information click here:

Clinicaltrials.gov Identifier : NCT00358150


Status: Active, not recruiting
Sponsored by: Sanofi Genzyme
Intervention: Drug: Genz-112638
Phase: Phase 2

2. Safety and Efficacy of Cerezyme ® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
This is a multicenter, randomized trial to compare the safety and efficacy of two dosing frequencies of Cerezyme® in patients with Gaucher disease who are currently being treated with Cerezyme®.

For more information click here:

Clinicaltrials.gov Identifier : NCT00364858


Status: Completed
Sponsored by: Sanofi Genzyme
Intervention: Cerezyme
Phase: Phase 4

3. Gene Therapy
Sanofi Genzyme is currently supporting clinical research in gene therapy for Parkinson’s disease, peripheral arterial disease and pre-clinical research in gene therapy for Gaucher disease.